For people with #RRP, the isolation, fear and debilitating impact of their disease is all too real. We’re working to deliver on the promise of #DNAMedicine and change the treatment paradigm for RRP and other HPV-related diseases. Learn more: www.INOVIO.com
INOVIO Pharmaceuticals, Inc.
Biotechnology Research
Plymouth Meeting, PA 24,910 followers
Powering DNA Medicines
About us
INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. Our mission: deliver on the promise of DNA medicine for patients around the world. For more information, visit www.inovio.com.
- Website
-
http://www.inovio.com
External link for INOVIO Pharmaceuticals, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Plymouth Meeting, PA
- Type
- Public Company
- Specialties
- DNA medicines, DNA plasmids, HPV-associated disease, cancer, infectious diseases, coronaviruses, immuno-oncology, dMAb (DNA-encoded monoclonal antibodies), immunotherapy, DNA vaccines, high-risk HPV, cervical dysplasia, cervical cancer, cervical HSIL, vulvar HSIL, anal HSIL, recurrent respiratory papillomatosis (RRP), HPV-associated cancers, head and neck cancer, glioblastoma, prostate cancer, Ebola, Zika, MERS, COVID-19, HIV, Lassa, T cells, SynCon, CELLECTRA, and electroporation
Locations
-
Primary
Get directions
660 West Germantown Pike, Suite 110
Plymouth Meeting, PA 19462, US
-
Get directions
10480 Wateridge Circle
San Diego, CA 92121, US
-
Get directions
6769 Mesa Ridge Rd
San Diego, California 92121, US
Employees at INOVIO Pharmaceuticals, Inc.
-
Nicole Nicks
Vice President FP&A and Accounting
-
Nicole Rich
Senior Director - Commercial Development at INOVIO Pharmaceuticals, Inc.
-
Laurent Humeau
Chief Scientific Officer and Executive Vice President of Research and Development
-
Shawn Bridy, MA, MBA
Senior Vice President, Business Development at INOVIO Pharmaceuticals, Inc.
Updates
-
To all of the patients with #RRP who have shared their stories, who are fighting for more treatment options, who are desperate to face even just one less surgery: we hear you.
-
For people with #RRP, the isolation, fear and debilitating impact of their disease is all too real. We’re working to deliver on the promise of #DNAMedicine and change the treatment paradigm for RRP and other HPV-related diseases. Learn more: www.INOVIO.com
-
-
6/11: the perfect day to highlight the strains of HPV that cause #RRP! Learn more about how we're designing DNA medicines to target HPV 6 & 11 and change the treatment paradigm for RRP & other HPV-related diseases at www.inovio.com
-
-
For people with #RRP, the isolation, fear and debilitating impact of their disease is all too real. We’re working to deliver on the promise of #DNAMedicine and change the treatment paradigm for RRP and other HPV-related diseases. Learn more: www. inovio.com
-
-
Happening next week: CEO Jacqui Shea and CMO Mike Sumner will join a fireside chat for institutional clients of Stephens, Inc. on June 11. Details: https://bit.ly/4e7qRV6
-
-
📣Calling all trailblazers: We’re looking for a Senior Director, Investor Relations to help share the potential of our innovative, next-generation DNA medicine platform with the investment community. Reporting to the CEO onsite at our headquarters in Plymouth Meeting, PA, this role will be pivotal in defining and implementing our IR strategy, promoting our value proposition, and driving progress toward our mission: delivering on the promise of DNA medicine for patients around the world. Interested? Reach out to Kate Rogers at [email protected] for more information.
-
-
Our business development team will be at the upcoming BIO International Convention to meet with colleagues and talk about the potential of #DNAMedicine. Reach out through the BIO partnering system if you want to connect in San Diego! #BIO2024
-
-
CEO Jacqui Shea on advancing lead candidate INO-3107 for RRP. Listen to more from our financial results conference call here: https://lnkd.in/eT5qcjQi
-
-
INOVIO reports first quarter financial results, along with recent operational highlights – read more here: https://bit.ly/3wCDNBt Key takeaways: ➡ BLA filing for INO-3107 on track for 2H24; Planning initiation of confirmatory trial based on FDA feedback ➡ Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZI(TM) (toripalimab-tpzi) as a potential treatment for throat cancer based on FDA feedback ➡ Balance sheet strengthened with public offering completed in April 2024 ➡ Cash runway projected into 3Q2025
-